Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 642-653

  Tarcha, Eric J ^a   Chi, Victor ^b   Muñoz Elías, Ernesto J ^a   Bailey, David ^d   Londono, Luz M ^a   Upadhyay, Sanjeev K ^b   Norton, Kayla ^a   Banks, Amy ^a   Tjong, Indra ^b   Nguyen, Hai ^b   Hu, Xueyou ^c   Ruppert, Greg W ^d   Boley, Scott E ^d   Slauter, Richard ^d   Sams, James ^d   Knapp, Brian ^d   Kentala, Dustin ^d   Hansen, Zachary ^d   Pennington, Michael W ^e   Beeton, Christine ^c   Chandy, K George ^b   Iadonato, Shawn P ^a   more..

^a Kineta Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MPI RESEARCH   (United States)

^e Peptides International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; PLACEBO; POTASSIUM CHANNEL KV1.3; PROTEIN INHIBITOR; SHK 186; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; INJECTION SITE; INTERMETHOD COMPARISON; MACACA FASCICULARIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY;

ABSORPTION; ANIMALS; ARTHRITIS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; KV1.3 POTASSIUM CHANNEL; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; POTASSIUM CHANNEL BLOCKERS; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SAIMIRI; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 84865173857     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.191890     Document Type: Article

References (41)

1. Audebert F, Urtizberea M, Sabouraud A, Scherrmann JM, and Bon C (1994) Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits. J Pharmacol Exp Ther 268:1512-1517. (Pubitemid 24100373)
2. Azam P, Sankaranarayanan A, Homerick D, Griffey S, and Wulff H (2007) Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127:1419-1429. (Pubitemid 46762978)
3. Barral-Netto M, Schriefer A, Vinhas V, and Almeida AR (1990) Enzyme-linked immunosorbent assay for the detection of Bothrops jararaca venom. Toxicon 28:1053-1061. (Pubitemid 20330357)
4. Beeton C and Chandy KG (2007) Induction and monitoring of active delayed type hypersensitivity (DTH) in rats. J Vis Exp 6:237.
5. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, et al. (2005) Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 67:1369-1381. (Pubitemid 40410438)
6. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 98:13942-13947.
7. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A 103:17414-17419. (Pubitemid 44788983)
8. Berg DK and Hall ZW (1975) Loss of α-bungarotoxin from junctional and extrajunctional acetylcholine receptors in rat diaphragm muscle in vivo and in organ culture. J Physiol 252:771-789.
9. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Mäcke HR, Chinol M, and Paganelli G (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase 1 study. Eur J Nucl Med Mol Imaging 30:207-216. (Pubitemid 36686839)
10. Cahalan MD and Chandy KG (2009) The functional network of ion channels in T lymphocytes. Immunol Rev 231:59-87.
11. Castañeda O, Sotolongo V, Amor AM, Stöcklin R, Anderson AJ, Harvey AL, Engstro ̈m A, Wernstedt C, and Karlsson E (1995) Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon 33:603-613.
12. Chang CC and Huang MC (1975) Turnover of junctional and extrajunctional acetylcholine receptors of the rat diaphragm. Nature 253:643-644.
13. Cheong A, Li J, Sukumar P, Kumar B, Zeng F, Riches K, Munsch C, Wood IC, Porter KE, and Beech DJ (2011) Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 blockers. Cardiovasc Res 89:282-289.
14. Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, et al. (2012) Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59:529-546.
15. Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, McNally J, Kitchens CS, Curry SC, Bogdan GM, et al. (2001) A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 161:2030-2036.
16. de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, Gekle M, Willnow TE, Walrand S, Jamar F, et al. (2005) Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 46:1696-1700. (Pubitemid 46211593)
17. Feurer C, Prentice DE, and Cammisuli S (1985) Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol 10:159-166. (Pubitemid 16205945)
18. Gilhar A, Bergman R, Assay B, Ullmann Y, and Etzioni A (2011) The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J Invest Dermatol 131:118-124.
19. Gillett A, Marta M, Jin T, Tuncel J, Leclerc P, Nohra R, Lange S, Holmdahl R, Olsson T, Harris RA, et al. (2010) TNF production in macrophages is genetically determined and regulates inflammatory disease in rats. J Immunol 185:442-450.
20. Gotthardt M, van Eerd-Vismale J, Oyen WJ, de Jong M, Zhang H, Rolleman E, Maecke HR, Béhé M, and Boerman O (2007) Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 48:596-601. (Pubitemid 47571416)
21. Grgic I, Wulff H, Eichler I, Flothmann C, Köhler R, and Hoyer J (2009) Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 41:2601-2606.
22. Gutiérrez JM, León G, and Lomonte B (2003) Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenoming. Clin Pharmacokinet 42:721-741.
23. Hu L, Gocke AR, Knapp E, Rosenzweig JM, Grishkan IV, Baxi EG, Zhang H, Margolick JB, Whartenby KA, and Calabresi PA (2012) Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling. J Biol Chem 287:1261-1268.
24. Hu L, Pennington M, Jiang Q, Whartenby KA, and Calabresi PA (2007) Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 179:4563-4570.
25. Hyodo T, Oda T, Kikuchi Y, Higashi K, Kushiyama T, Yamamoto K, Yamada M, Suzuki S, Hokari R, Kinoshita M, et al. (2010) Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol 299:F1258-F1269.
26. Ismail M, Aly MH, Abd-Elsalam MA, and Morad AM (1996) A three-compartment open pharmacokinetic model can explain variable toxicities of cobra venom and their alpha toxins. Toxicon 34:1011-1026. (Pubitemid 26320011)
27. Keith AB, Arnon R, Teitelbaum D, Caspary EA, and Wisniewski HM (1979) The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 42:267-274. (Pubitemid 9183660)
28. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, Shah K, Mulvany K, Hora D Jr, Cunningham P, et al. (1997) Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 158:5120-5128. (Pubitemid 127681213)
29. Lassmann H and Wisniewski HM (1979) Chronic relapsing experimental allergic encephalomyelitis: effect of age at the time of sensitization on clinical course and pathology. Acta Neuropathol 47:111-116. (Pubitemid 10192435)
30. Lorentzen JC, Issazadeh S, Storch M, Mustafa MI, Lassman H, Linington C, Klareskog L, and Olsson T (1995) Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 63:193-205. (Pubitemid 26019013)
31. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, et al. (2008) Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29:602-614.
32. Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, et al. (2009) Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol 75:762-773.
33. Pennington MW, Mahnir VM, Khaytin I, Zaydenberg I, Byrnes ME, and Kem WR (1996) An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry 35:16407-16411. (Pubitemid 27020479)
34. Raine CS, Snyder DH, Stone SH, and Bornstein MB (1977) Suppression of acute and chronic experimental allergic encephalomyelitis in Strain 13 guinea pigs. A clinical and pathological study. J Neurol Sci 31:355-367. (Pubitemid 8055806)
35. Rangaraju S, Chi V, Pennington MW, and Chandy KG (2009) Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin Ther Targets 13:909-924.
36. Rintisch C, Förster M, and Holmdahl R (2009) Detection of arthritis-susceptibility loci, including Ncf1, and variable effects of the major histocompatibility complex region depending on genetic background in rats. Arthritis Rheum 60:419-427.
37. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, et al. (2005) The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory brain infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 102:11094-11099. (Pubitemid 41105998)
38. Seifert SA and Boyer LV (2001) Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med 37:189-195. (Pubitemid 32142967)
39. Soler D, Humphreys TL, Spinola SM, and Campbell JJ (2003) CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 101:1677-1682.
40. + channel in effector memory T cells as new target for MS. J Clin Invest 111:1703-1713.
41. + channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97:8151-8156.